Nymox Pharmaceutical Price to Book Value
View 4,000+ financial data types
Nymox Pharmaceutical Price to Book Value Chart
Nymox Pharmaceutical Historical Price to Book Value Data
|Data for this Date Range|
There is no data for the selected date range.
An error occurred. Please try again by refreshing your browser or contact us with details of your problem.
About Price to Book Ratio
Price to book value is a financial ratio used to compare a company's book value to its current market price. Book value is an accounting term denoting the portion of the company held by the shareholders at accounting value (not market value). In other words, book value is the company's total tangible assets less its total liabilities.
The ratio has two calculation methods. In the first way, the company's market capitalization is divided by the company's total book value from its balance sheet. The second way, using per-share values, is to divide the company's current share price by the book value per share. In general, a low price to book value indicates that a stock is undervalued and thus more desirable.
In theory, if you purchased stock with a price to book value less than 1 and the company immediately went bankrupt, you would gain money on your investment. In reality, this may not be true since there are times when liquidation value, or the price at which a company's assets can be sold, is less than the book value of those assets.
For more information on evaluating valuation multiples similar to this, please see our original white paper research : Making Sense Of Valuation Multiples.
NYMX Price to Book Value Benchmarks
NYMX Price to Book Value Excel Add-In Codes
- Metric Code: price_to_book_value
- Latest data point: =YCP("NYMX", "price_to_book_value")
- Last 5 data points: =YCS("NYMX", "price_to_book_value", -4)
To find the codes for any of our financial metrics, see our Complete Reference of Metric Codes.
Access our powerful Excel Add-in with a YCharts Professional Membership. Learn More.
Yahoo 12/18 12:01 ET
GlobeNewswire 12/18 12:00 ET
PR Newswire 12/08 09:11 ET